Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 2.53B +176.8% |
| Revenue (ttm) | n/a |
| Net Income | -98.78M |
| EPS | -1.65 |
| Shares Out | 60.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 632,207 |
| Open | 42.81 |
| Previous Close | 42.25 |
| Day's Range | 41.43 - 43.05 |
| 52-Week Range | 14.79 - 48.53 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 57.00 (+37.22%) |
| Earnings Date | May 7, 2026 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $57.0, which is an increase of 37.22% from the latest price.
News
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
Enliven (ELVN) Therapeutics announced additional data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia in an abstract accepted for an oral presentat...
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously ...
Guggenheim starts Enliven with Buy on leukemia opportunity
Guggenheim last night initiated coverage of Enliven (ELVN) with a Buy rating and $80 price target The company is focused on the discovery and development of small molecule therapeutics, the…
Enliven initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Enliven (ELVN) with a Buy rating and $80 price target
Enliven price target raised to $59 from $41 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Enliven (ELVN) to $59 from $41 and keeps a Buy rating on the shares. Enliven reported Q1 results and reaffirmed timelines for…
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash...
Enliven Therapeutics Quarterly report: Q1 2026
Enliven Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Enliven Therapeutics Earnings release: Q1 2026
Enliven Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
Mizuho reiterated an Outperform rating and $45 price target on Enliven (ELVN) after Merck (MRK) noted during its Q1 call that it believes Terns’ (TERN) TERN-701 major molecular response “will…
Enliven Therapeutics Proxy statement: Proxy filing
Enliven Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Enliven Therapeutics Proxy statement: Proxy filing
Enliven Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Enliven price target raised to $55 from $36 at Clear Street
Clear Street raised the firm’s price target on Enliven (ELVN) to $55 from $36 and keeps a Buy rating on the shares. The firm left meetings with management with increased…
Enliven Therapeutics Proxy statement: Proxy filing
Enliven Therapeutics filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Enliven price target raised to $56 from $48 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $56 from $48 and keeps a Buy rating on the shares. The firm believes Merck’s (MRK) acquisition of Terns…
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
Shares of Enliven Therapeutics (ELVN) are up nearly 20% to $37.22 in pre-market trading after rival drug developer Terns Pharmaceuticals (TERN) announced an agreement to be acquired by pharma giant…
Enliven price target raised to $45 from $41 at Mizuho
Mizuho raised the firm’s price target on Enliven (ELVN) to $45 from $41 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q4…
Enliven Therapeutics Annual report: Q4 2025
Enliven Therapeutics has published its Q4 2025 annual report on March 3, 2026.
Enliven Therapeutics Earnings release: Q4 2025
Enliven Therapeutics released its Q4 2025 earnings on March 3, 2026, summarizing the period's financial results.
Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
ELVN-001 is advancing to phase 3 for CML, showing strong efficacy and safety in heavily pretreated patients. The company is well-funded, targeting a $9B US market, and plans to present updated data in June, with regulatory milestones expected by year-end.
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of...
Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML
Enliven (ELVN) Therapeutics announced positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia that is relapsed, refractory o...
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable s...
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 202...